-
Overview
Date & Location
03/19/2021 – 03/19/2021, 12:00 AM CST Online
Overview
This episode reflects on the progression of COVID treatments one year in, and discusses the biggest advances in the treatment for COVID-19 over the past year. Lessons learned from the ACT2 trial study are discussed as well as lessons learned from other trials. Preliminary studies on monulpiravir, and oral antiviral drug, is also discussed.
Target Audience
This educational activity is designed to meet the educational goals of physicians and other healthcare professionals specializing in infectious diseases, family and community medicine, internal medicine, emergency medicine, and all those involved with the management of patients with coronavirus.
Learning Objectives for the Episode 6
- Discuss the biggest advances in COVID-19.
- Discuss beneficial agents in preventing COVID-19.
- Discuss the role of anti-virals in the treatment of COVID-19.
- Discuss preliminary studies of monulpiravir.
Program Registration Information
Registration Fees - $0.00
Continuing Medical Education Education Credit - Accreditation and Designation Statement
University of Texas Health Science Center at San Antonio is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
University of Texas Health Science Center at San Antonio designates this enduring material for a maximum of .50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Certificate of Attendance
Healthcare professionals will receive a certificate of attendance and are asked to consult with their licensing board for information on applicability and acceptance.
Credit may be obtained upon successful completion of the activity’s evaluation.
Release date: 03/19/2021 Credits expire: 03/19/2022
-
Faculty
Jan E. Patterson, MD, MS, MACP
FIDSA, FSHEA, CHCP
Professor of Medicine/Infectious Diseases and Pathology
Associate Dean for Quality & Lifelong Learning
Joe R. and Teresa Lozano Long School of Medicine
UT Health San AntonioDr. Patterson is a Professor of Medicine/Infectious Diseases and Associate Dean for Quality & Lifelong Learning at The Joe R. and Teresa Lozano Long School of Medicine, UT Health San Antonio. She is clinician and a healthcare epidemiologist and has served on the Infectious Diseases Society of America Board of Directors and is Past President of the Society for Healthcare Epidemiology of America. She is a longtime infectious diseases consultant to Southwest Texas Regional Advisory Council (STRAC) and has also served on CDC’s Healthcare Infection Practices Advisory Committee and has been a consultant to San Antonio Metro Health Department. She has been a site principal investigator for new antimicrobial agents and is currently a co-investigator for the NIH Adaptive COVID-19 Treatment Trial (ACTT) studies as outlined above and is a sub-investigator for the Novavax SARS-CoV-2 vaccine trial at UT Health and University Hospital.
Phil Ponce, MD
Assistant Professor of Medicine/Infectious Diseases
Joe R. and Teresa Lozano Long School of Medicine
UT Health San Antonio
Medical Director Transplant Infectious Diseases, University HealthDr. Ponce is currently an Assistant Professor of Infectious Diseases at UT Health San Antonio. His usual clinical responsibilities include serving as the Director of Transplant ID at the University Transplant Center and the Medical Director of the Kind Clinic, a nonprofit clinic focused on STI testing and treatment, HIV prevention, and HIV care. Since the advent of the COVID epidemic he has been a site co-investigator on the NIH ACTT and ACTIV clinical trials at UT Health San Antonio. He is the COVID ID liaison to the Hospital Medicine service, helping to develop the University Hospital treatment protocols, and is a regular attending on the inpatient COVID ID consult service.
Relevant Financial Disclosures
Dr. Jan Patterson has disclosed that she is a NIH ACTT co-investigator and sub-investigator for the Novavax SARS-CoV-2 vaccine trial and recieves honorarium from Pfizer.
Dr. Phil Ponce has disclosed that he is NIH ACTT co-investigator and sub-investigator on the Novavax SARS-Co-V-2 vaccine trial.
Logins
Find
Events
Technology
Episode 5 - Monoclonal Antibodies for COVID-19
-
Overview
Date & Location
12/15/2020 – 12/15/2021, 12:00 AM CST Online
Overview
This episode describes monoclonal antibodies bamlanivimab and casirivimab/imdevimab and the FDA Emergency Use Authorization for these agents. Criteria for use, including patients who are eligible and not eligible for this therapy are discussed, and potential benefits of therapy. The Regional Infusion Center, a unique collaboration between the Regional Advisory Council, San Antonio Fire and EMS, and local hospitals, is described and discussed.
Target Audience
This educational activity is designed to meet the educational goals of physicians and other healthcare professionals specializing in infectious diseases, family and community medicine, internal medicine, emergency medicine, and all those involved with the management of patients with coronavirus.
Learning Objectives for the Episode 5
- Describe the monoclonal antibodies and their potential benefit.
- List those who are eligible to recieve monoclonal antibodies for potential benefit.
- List those who are not eligible to recieve monoclonal antibodies.
- Describe the Regional Infusion Center that is a result of collaboration in San Antonio area.
Program Registration Information
Registration Fees - $0.00
Continuing Medical Education Education Credit - Accreditation and Designation Statement
The Joe R. and Teresa Lozano Long School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Long School of Medicine designates this enduring material for a maximum of .50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Certificate of Attendance
Healthcare professionals will receive a certificate of attendance and are asked to consult with their licensing board for information on applicability and acceptance.
Credit may be obtained upon successful completion of the activity’s evaluation.
Release date: 12/15/2020 Credits expire: 12/15/2021
-
Faculty
Jan E. Patterson, MD, MS, MACP
FIDSA, FSHEA, CHCP
Professor of Medicine/Infectious Diseases and Pathology
Associate Dean for Quality & Lifelong Learning
Joe R. and Teresa Lozano Long School of Medicine
UT Health San AntonioDr. Patterson is a Professor of Medicine/Infectious Diseases and Associate Dean for Quality & Lifelong Learning at The Joe R. and Teresa Lozano Long School of Medicine, UT Health San Antonio. She is clinician and a healthcare epidemiologist and has served on the Infectious Diseases Society of America Board of Directors and is Past President of the Society for Healthcare Epidemiology of America. She is a longtime infectious diseases consultant to Southwest Texas Regional Advisory Council (STRAC) and has also served on CDC’s Healthcare Infection Practices Advisory Committee and has been a consultant to San Antonio Metro Health Department. She has been a site principal investigator for new antimicrobial agents and is currently a co-investigator for the NIH Adaptive COVID-19 Treatment Trial (ACTT) studies as outlined above and is a sub-investigator for the Novavax SARS-CoV-2 vaccine trial at UT Health and University Hospital.
C. J. Winckler, MD
Assistant Professor/Clinical
Deputy Medical Director, San Antonio Fire Department
Joe R. and Teresa Lozano Long School of Medicine
UT Health San AntonioDr. C. J. Winckler is an Assistant Professor of Emergency Health Services at UT Health San Antonio and Deputy Medical Director for the San Antonio Fire Department / Emergency Medical Services.
Relevant Financial Disclosures
Dr. Jan Patterson has disclosed that she is a NIH ACTT co-investigator and sub-investigator for the Novavax SARS-CoV-2 vaccine trial.
Dr. C.J. Winckler does not have any relevant financial relationships to disclose.
Episode 4 - Vaccine Update
-
Overview
Date & Location
12/9/2020 – 12/9/2021, 12:00 AM CST Online
Overview
This podcast discusses the latest updates on vaccine trials to include the development processes used for the leading vaccine candidates. Strategies for the development of these vaccines is discussed and the timeline for vaccine distribution is also outlined. Finally, Dr. Taylor discusses what she believes our world will look like once vaccines are available.
Target Audience
This educational activity is designed to meet the educational goals of physicians and other healthcare professionals specializing in infectious diseases, family and community medicine, internal medicine, emergency medicine, and all those involved with the management of patients with coronavirus.
Learning Objectives for the Episode 4
- Describe the vaccine development processes used for leading COVID-19 vaccine candidates.
- Compare and contrast the leading COVID-19 vaccine candidates.
- Outline the timeline for COVID-19 vaccine distribution.
- Describe what a post-vaccine world will look like in the short-term and in the long-term.
Program Registration Information
Registration Fees - $0.00
Continuing Medical Education Education Credit - Accreditation and Designation Statement
The Joe R. and Teresa Lozano Long School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Long School of Medicine designates this enduring material for a maximum of .50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Certificate of Attendance
Healthcare professionals will receive a certificate of attendance and are asked to consult with their licensing board for information on applicability and acceptance.
Credit may be obtained upon successful completion of the activity’s evaluation.
Release date: 12/9/2020 Credits expire: 12/9/2021
-
Faculty
Jan E. Patterson, MD, MS, MACP
FIDSA, FSHEA, CHCP
Professor of Medicine/Infectious Diseases and Pathology
Associate Dean for Quality & Lifelong Learning
Joe R. and Teresa Lozano Long School of Medicine
UT Health San AntonioDr. Patterson is a Professor of Medicine/Infectious Diseases and Associate Dean for Quality & Lifelong Learning at The Joe R. and Teresa Lozano Long School of Medicine, UT Health San Antonio. She is clinician and a healthcare epidemiologist and has served on the Infectious Diseases Society of America Board of Directors and is Past President of the Society for Healthcare Epidemiology of America. She is a longtime infectious diseases consultant to Southwest Texas Regional Advisory Council (STRAC) and has also served on CDC’s Healthcare Infection Practices Advisory Committee and has been a consultant to San Antonio Metro Health Department. She has been a site principal investigator for new antimicrobial agents and is currently a co-investigator for the NIH Adaptive COVID-19 Treatment Trial (ACTT) studies as outlined above and is a sub-investigator for the Novavax SARS-CoV-2 vaccine trial at UT Health and University Hospital.
Barbara S. Taylor, MD, MS
Associate Professor of Infectious Diseases
Assistant Dean for the MD/MPH Program
Joe R. and Teresa Lozano Long School of Medicine
UT Health San AntonioDr. Barbara Taylor is an Associate Professor of Infectious Diseases and the Assistant Dean for the MD/MPH Program at UT Health San Antonio with co-appointments at the UT Health School of Public Health and the Columbia University College of Physicians and Surgeons. She has disclosed that she is a principal investigator for the COVID-19 Prevention Network.
Relevant Financial Disclosures
Dr. Jan Patterson has disclosed that she is a NIH ACTT co-investigator and sub-investigator for the Novavax SARS-CoV-2 vaccine trial.
Dr. Barbara Taylor has disclosed that she is a principal investigator for the COVID-19 Prevention Network.
Episode 3 - Outpatient Management Strategies for COVID-19
-
Overview
Date & Location
11/24/2020 - 11/24/2021, 12:00AM CST Online
Overview
This is a conversation with Dr. Ruth Berggren, Professor of Medicine/Infectious Diseases and Director, Center for Medical Humanities and Ethics at UT Health San Antonio, regarding outpatient management strategies for COVID-19. General recommendations are discussed, as well as the use of monoclonal antibodies and the off-label use of supplements and medications for which there is some preliminary data.
Target Audience
This educational activity is designed to meet the educational goals of physicians and other healthcare professionals specializing in infectious diseases, family and community medicine, internal medicine, emergency medicine, and all those involved with the management of patients with coronavirus.
Learning Objectives for the Episode 3
- List equipment recommended for the outpatient with COVID-19
- Discuss the role of monoclonal antibodies in the treatment of COVID-19
- List supplements and mediciations that have shown promise in the preliminary studies for coronavirus infection (off-label use).
Program Registration Information
Registration Fees - $0.00
Continuing Medical Education Education Credit - Accreditation and Designation Statement
The Joe R. and Teresa Lozano Long School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Long School of Medicine designates this enduring material for a maximum of .50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Certificate of Attendance
Healthcare professionals will receive a certificate of attendance and are asked to consult with their licensing board for information on applicability and acceptance.
Credit may be obtained upon successful completion of the activity’s evaluation.
Release date: 11/24/2020 Credits expire: 11/24/2021
-
Faculty
Jan E. Patterson, MD, MS, MACP
FIDSA, FSHEA, CHCP
Professor of Medicine/Infectious Diseases and Pathology
Associate Dean for Quality & Lifelong Learning
Joe R. and Teresa Lozano Long School of Medicine
UT Health San AntonioDr. Patterson is a Professor of Medicine/Infectious Diseases and Associate Dean for Quality & Lifelong Learning at The Joe R. and Teresa Lozano Long School of Medicine, UT Health San Antonio. She is clinician and a healthcare epidemiologist and has served on the Infectious Diseases Society of America Board of Directors and is Past President of the Society for Healthcare Epidemiology of America. She is a longtime infectious diseases consultant to Southwest Texas Regional Advisory Council (STRAC) and has also served on CDC’s Healthcare Infection Practices Advisory Committee and has been a consultant to San Antonio Metro Health Department. She has been a site principal investigator for new antimicrobial agents and is currently a co-investigator for the NIH Adaptive COVID-19 Treatment Trial (ACTT) studies as outlined above and is a sub-investigator for the Novavax SARS-CoV-2 vaccine trial at UT Health and University Hospital.
Ruth Berggren, MD, MACP
Professor of Medicine/Infectious Diseases
Joe R. and Teresa Lozano Long School of Medicine
Director, Center for Medical Humanities and Ethics
UT Health San AntonioDr. Berggren is a Professor of Medicine/Infectious Diseases at The Joe R. and Teresa Lozano Long School of Medicine and directs the Center for Medical Humanities & Ethics at UT Health San Antonio. In this role, she teaches ethics and professionalism while nurturing empathy and humanitarian values. The Center focuses on four areas: ethics and professionalism; global health; community service learning; and the medical humanities (literature, music and art).
Dr. Berggren arrived at UT Health San Antonio in fall 2006 after an eventful stint at New Orleans’ Charity Hospital, where she stood by her mostly uninsured patients in the HIV ward during Hurricane Katrina until all were safely evacuated six days later. She reflected on the experience in articles published in the New England Journal of Medicine and a commencement address to the Health Science Center School of Medicine. Her determination to inspire humanism in medicine and effect change through her own experiences led to her being named director of the Center for Medical Humanities & Ethics in October 2007.
The daughter of public health physicians, Dr. Berggren spent her childhood at Haiti’s Hôpital Albert Schweitzer, named for the Nobel Prize-winning physician and humanitarian known for his philosophy of reverence for life. During medical school, she was named an Albert Schweitzer Fellow and traveled to the West African nation of Gabon to work at the hospital established by Dr. Schweitzer. Her involvement in global health and ties to Haiti continue today. Following the 2010 earthquake in Haiti, Dr. Berggren was active in relief efforts along the Haitian-Dominican border. She lectured widely on these experiences and on disaster preparedness for the American College of Physicians, Centers for Disease Control, American Medical Association, Pan American Health Organization and medical schools nationwide.
Relevant Financial Disclosures
Dr. Jan Patterson has disclosed that she is a NIH ACTT co-investigator and sub-investigator for the Novavax SARS-CoV-2 vaccine trial.
Dr. Ruth Berggren has disclosed that she is a sub-investigator for the Sinai vaccine trial.
Episode 2 - Testing and Prevention Strategies
-
Overview
Date & Location
11/11/2020 - 11/11/2021, 12:00AM CST Online
Overview
This podcast discusses testing strategies and updates as well as prevention strategies for COVID-19 to include PCR testing, antigen testing and the role of antibody testing. COVID-19 infection control and lessons learned is also discussed.
Target Audience
This educational activity is designed to meet the educational goals of physicians and other healthcare professionals specializing in infectious diseases, family and community medicine, internal medicine, emergency medicine, and all those involved with the management of patients with coronavirus.
Learning Objectives for the Episode 2
- Discuss PCR testing, Antigen testing, and the role of antibody testing and its advantages and disadvantages.
- Discuss hospital control measures and what has been learned from the COVID-19 pandemic
Program Registration Information
Registration Fees - $0.00
Continuing Medical Education Education Credit - Accreditation and Designation Statement
The Joe R. and Teresa Lozano Long School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Long School of Medicine designates this enduring material for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Certificate of Attendance
Healthcare professionals will receive a certificate of attendance and are asked to consult with their licensing board for information on applicability and acceptance.
Credit may be obtained upon successful completion of the activity’s evaluation.
Release date: 11/11/2020 Credits expire: 11/11/2021
-
Faculty
Jan E. Patterson, MD, MS, MACP
FIDSA, FSHEA, CHCP
Professor of Medicine/Infectious Diseases and Pathology
Associate Dean for Quality & Lifelong Learning
Joe R. and Teresa Lozano Long School of Medicine
UT Health San AntonioDr. Patterson is a Professor of Medicine/Infectious Diseases and Associate Dean for Quality & Lifelong Learning at The Joe R. and Teresa Lozano Long School of Medicine, UT Health San Antonio. She is clinician and a healthcare epidemiologist and has served on the Infectious Diseases Society of America Board of Directors and is Past President of the Society for Healthcare Epidemiology of America. She is a longtime infectious diseases consultant to Southwest Texas Regional Advisory Council (STRAC) and has also served on CDC’s Healthcare Infection Practices Advisory Committee and has been a consultant to San Antonio Metro Health Department. She has been a site principal investigator for new antimicrobial agents and is currently a co-investigator for the NIH Adaptive COVID-19 Treatment Trial (ACTT) studies as outlined above and is a sub-investigator for the Novavax SARS-CoV-2 vaccine trial at UT Health and University Hospital.
Jason Bowling, MD
Associate Professor of Medicine/Infectious Diseases
Joe R. and Teresa Lozano Long School of Medicine
UT Health San AntonioDr. Bowling is an Associate Professor of Medicine, Division of Infectious Diseases at the Joe R. and Teresa Lozano Long School of Medicine, UT Health San Antonio. He is a clinician and a healthcare epidemiologist at University Health. He is also an investigator for the Adaptive COVID-19 Treatment Trial (ACTT) conducted at University Hospital and a sub-investigator for the Novavax SARS-CoV-2 vaccine trial at UT Health and University Hospital.
Relevant Financial Disclosures
Dr. Jan Patterson has disclosed that she is a NIH ACTT co-investigator and sub-investigator for the Novavax SARS-CoV-2 vaccine trial.
Dr. Jason Bowling has disclosed that he is an NIH ACTT co- investigator and sub-investigator for the Novavax SARS-CoV-2 vaccine trial.
Episode 1: New and Emerging Therapies for COVID-19
-
Overview
Date & Location
11/8/2020 - 11/8/2021, 12:00AM CST Online
Overview
This podcast discusses new and emerging therapies for COVID-19 to include the efficacy of the antiviral remdesivir and it use in COVID-19 patients as well as other candidate treatments currently being studied for COVID-19 hospitalized patients. The potential role of monoclonal antibodies in COVID-19 treatment is also discussed.
Target Audience
This educational activity is designed to meet the educational goals of physicians and other healthcare professionals specializing in infectious diseases, family and community medicine, internal medicine, emergency medicine, and all those involved with the management of patients with coronavirus.
Learning Objectives for the Episode 1
- Discuss the efficacy of the antiviral remdesivir and when it should be used in COVID-19 patients
- List other candidate treatments being studied for the treatment of COVID-19 in hospitalized patients
- Describe the potential role of monoclonal antibodies in treating COVID-19
Program Registration Information
Registration Fees - $0.00
Continuing Medical Education Education Credit - Accreditation and Designation Statement
The Joe R. and Teresa Lozano Long School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Long School of Medicine designates this enduring material for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Certificate of Attendance
Healthcare professionals will receive a certificate of attendance and are asked to consult with their licensing board for information on applicability and acceptance.
Credit may be obtained upon successful completion of the activity’s evaluation.
Release date: 11/8/2020 Credits expire: 11/8/2021
-
Faculty
Jan E. Patterson, MD, MS, MACP
FIDSA, FSHEA, CHCP
Professor of Medicine/Infectious Diseases and Pathology
Associate Dean for Quality & Lifelong Learning
Joe R. and Teresa Lozano Long School of Medicine
UT Health San AntonioDr. Patterson is a Professor of Medicine/Infectious Diseases and Associate Dean for Quality & Lifelong Learning at The Joe R. and Teresa Lozano Long School of Medicine, UT Health San Antonio. She is clinician and a healthcare epidemiologist and has served on the Infectious Diseases Society of America Board of Directors and is Past President of the Society for Healthcare Epidemiology of America. She is a longtime infectious diseases consultant to Southwest Texas Regional Advisory Council (STRAC) and has also served on CDC’s Healthcare Infection Control Practices Advisory Committee and has been a consultant to the City of San Antonio Metro Health Department. She has been a site principal investigator for new antimicrobial agents and is currently a co-investigator for the NIH ACTT studies as outlined above and is a sub-investigator for the Novavax SARS-CoV-2 vaccine trial at UT Health SA and University Hospital.
Thomas F. Patterson, MD
Professor of Medicine/Infectious Diseases and Pathology
Division Chief, Infectious Diseases
Vice Chair for Faculty Development
Joe R. and Teresa Lozano Long School of Medicine
UT Health San AntonioDr. Patterson is a Professor of Medicine and Chief, Division of Infectious Diseases and serves as the Vice-Chair for Faculty Development in the Department of Medicine at The Joe R. and Teresa Lozano Long School of Medicine, UT Health San Antonio. He is a clinician and longtime clinical investigator, particularly in the development of new antifungal drugs and in clinical trials of new antifungal compounds. He has had long-term funding from the NIH and industry for grants and contracts on drug and diagnostic development. During this COVID-19 pandemic, Dr. Patterson leads the UT Health Division of Infectious Diseases efforts in clinical management of COVID-19 care and is the site principal investigator for the Adaptive COVID-19 Treatment Trial (ACTT) conducted at University Hospital and supported by the National Institutes of Health to develop safe and effective therapies against COVID-19. He is a sub-investigator for the Novavax SARS-CoV-2 vaccine trial at UT Health SA and University Hospital.
Relevant Financial Disclosures
Dr. Jan Patterson has disclosed that she is a NIH ACTT co-investigator and sub-investigator for the Novavax SARS-CoV-2 vaccine trial. She is the spouse of Dr. Thomas Patterson.
Dr. Tom Patterson has disclosed that he is a NIH ACTT investigator and sub-investigator for the Novavax SARS-CoV-2 vaccine trial. He is the spouse of Dr. Jan Patterson.
